Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Healios KK ( (JP:4593) ) has issued an announcement.
Healios K.K. has announced changes in its management and organizational structure, effective January 1, 2026. Notably, Yoshie Tsurumaki will become an Executive Officer, leveraging her extensive experience in cell therapy and oncology to lead the newly established Medical Affairs Division. This strategic move is expected to enhance the company’s engagement with healthcare professionals and improve the medical value of its products, potentially strengthening its position in the regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. operates in the biotechnology industry, focusing on the development and commercialization of regenerative medicine and cell therapy products. The company aims to advance medical treatments through innovative therapies, particularly in areas like oncology and gene therapy.
Average Trading Volume: 2,275,879
Technical Sentiment Signal: Sell
Current Market Cap: Yen49.07B
Learn more about 4593 stock on TipRanks’ Stock Analysis page.